nach oben

08.03.2024 | Review

An Overview of the Clinical Implications of Cirrhotic Cardiomyopathy

verfasst von: Sarah Myers, Pakinam Mekki, Manhal Izzy

Erschienen in: Current Hepatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cirrhotic cardiomyopathy (CCM) is a clinical entity that reflects the maladaptive responses of the heart to advanced chronic liver disease. With the recent developments in this field, this review details the most up to date knowledge about the pathogenesis of CCM, recent changes in its diagnostic criteria, and its clinical relevance.

Recent Findings

Advances in echocardiographic techniques over the last several years and recent research have highlighted the high prevalence of CCM approaching 35% and demonstrated adverse impact of CCM on clinical outcomes following transjugular intrahepatic portosystemic shunting (TIPS) and liver transplantation (LT).

Summary

The diagnostic criteria for cirrhotic cardiomyopathy have evolved with advancements in echocardiographic techniques allowing for precise and perhaps timely identification of those with subclinical cardiac impairment. CCM increases the risk for adverse outcomes in patients with cirrhosis and liver transplant recipients. Future studies are needed to identify subgroups of patients at highest risk for cirrhotic cardiomyopathy, the frequency and duration of monitoring for those with CCM, and potential therapeutics for patients with cirrhosis and liver transplant who have been diagnosed with cirrhotic cardiomyopathy.

•• Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl. 2021;27(6):876–86. https://doi.org/10.1002/lt.26000. Original study identifying the prevalence of Cirrhotic Cardiomyopathy with new diagnostic criteria as well as increased cardiovascular risk that the diagnosis conveys.CrossRefPubMed

Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatol. 1996;24(2):451–9. https://doi.org/10.1002/hep.510240226.CrossRef

•• Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatol. 2020;71(1):334–345. https://doi.org/10.1002/hep.30875. Erratum in: Hepatol. 2020:Sep;72(3):1161. The Cirrhotic Cardiomyopathy Consortium Recommendations for the new diagnostic criteria of Cirrhotic Cardiomyopathy.

Liu H, Yoon KT, Zhang J, Lee SS. Advances in cirrhotic cardiomyopathy. Curr Opin Gastroenterol. 2021;37(3):187–93. https://doi.org/10.1097/MOG.0000000000000733.CrossRefPubMed

Yoon KT, Liu H, Lee SS. Cirrhotic cardiomyopathy. Curr Gastroenterol Rep. 2020;22(9):45.CrossRefPubMed

• Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem. 2022;636:114388. https://doi.org/10.1016/j.ab.2021.114388. Comprehensive review of the complex pathophysiology of the development of cirrhotic cardiomyopathy.CrossRefPubMed

Ma A, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267(1 Pt 1):G87-93. https://doi.org/10.1152/ajpgi.1994.267.1.G87.CrossRefPubMed

Garcia-Estan J, Ortiz CM, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci. 2002;102(2):213–22.CrossRef

•• Matyas C, et al. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nature. 2021;18:117–35. Extensive review of the pathophysiologic mechanisms associated with the development of the extrahepatic complications associated with cirrhosis.

10.

Desai M, Mathur B, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen S, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology. 2017;65(1):189–201. https://doi.org/10.1002/hep.28890.CrossRefPubMed

11.

Kinno M, Izzy M. Editorial: The interplay of bile acids and the heart— another piece in the puzzle of cirrhotic cardiomyopathy. Aliment Pharmacol Ther. 2023;58:486–7. https://doi.org/10.1111/apt.17600.CrossRefPubMed

12.

Wiese S, Danielsen KV, Busk T, Hove JD, Ytting H, Hansen SH, et al. Altered serum bile acid composition is associated with cardiac dysfunction in cirrhosis. Aliment Pharmacol Ther. 2023;58(4):453–62. https://doi.org/10.1111/apt.17533.CrossRefPubMed

13.

Isaak A, Praktiknjo M, Jansen C, et al. Myocardial fibrosis and inflammation in liver cirrhosis: MRI study of the liver-heart axis. Radiol. 2020. https://doi.org/10.1148/radiol.2020201057.CrossRef

14.

• Spann A, Coe C, Teminioluwa A, et al. Cirrhotic cardiomyopathy: appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes. Liver Transpl. 2022;28:1321–31. https://doi.org/10.1002/lt.26460. Original study identifying echocardiographic criteria most likely to predict major adverse cardiac events post-transplant in patients with cirrhotic cardiomyopathy.CrossRefPubMedPubMedCentral

15.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRefPubMed

16.

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.CrossRefPubMed

17.

Slawin’ski G, Hawryszko M, Liz’ewska-Springer A, Nabialek-Trojanowska I, Lewicka E. Global longitudinal strain in cardio-oncology: a review. Cancers. 2023;15:1986. https://doi.org/10.3390/cancers15030986.

18.

Meucci MC, Strating MH, Butcher SC, Van Rijswijk CSP, Van Hook B, Delgado V, et al. Left atrial dysfunction is an independent predictor of mortality in patients with cirrhosis treated by transjugular intrahepatic portosystemic shunt. Hepatol Commun. 2022;6:3163–74. https://doi.org/10.1002/hep4.2062.CrossRefPubMedPubMedCentral

19.

Luo Y, Yin S, Chen Q, Liu J, Chong Y, Zhong J. Comparison of the 2005 Montreal Criteria and the 2019 Cirrhotic Cardiomyopathy Consortium Criteria for the Diagnosis of Cirrhotic Cardiomyopathy. Am J Cardiol. 2023;208:180–9.CrossRefPubMed

20.

Razpotnik M, Bota S, Wimmer P, Hackl M, Lesnik G, Abler H, et al. The prevelence of cirrhotic cardiomyopathy according to different diagnostic criteria. Liner Int. 2021;41(5):1058–69.

21.

Kockritz F, Braun A, Schmuck R, Dobrindt E, Eurich D, Heinzel F, et al. Speckle tracking analysis reveals altered left atrial and ventricular myocardial deformation in patients with end-stage liver disease. J Clin Med. 2021;10(5):897.CrossRef

22.

Lee SK, Song MJ, Kim SH, Ahn HJ. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clin Mol Hepatol. 2018;24(4):409–16.CrossRefPubMedPubMedCentral

23.

• Kajal K, Premkumar M, Izzy M, Kulkarni AV, Duseja AK, Divyaveer S, et al. Cirrhotic cardiomyopathy influences clinical outcomes and enhances performance of conventional risk prediction models in acute-on-chronic liver failure with severe sepsis. Aliment Pharmacol Ther. 2023;00:1–17. https://doi.org/10.1111/apt.17695. A prospective evaluation of the impact of CCM on the clinical course of patients with cirrhosis and ACLF.

24.

Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, Péron JM, Lairez O, Bureau C. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: The Toulouse Algorithm. Hepatol. 2019;70(6):1928–41. https://doi.org/10.1002/hep.30934.CrossRef

25.

• Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy M, et al. Advancing liver therapeutic approaches (ALTA) Consortium. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin Gastroenterol Hepatol. 2022;20(8):1636–1662.e36. https://doi.org/10.1016/j.cgh.2021.07.018. Consensus statements outlining management considerations for patients undergoing TIPS with cirrhotic cardiomyopathy.

26.

Izzy M, Fortune BE, Serper M, Bhave N, deLemos A, Gallegos-Orozco JF, et al. Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations. Am J Transplant. 2022;22(12):2740–58. https://doi.org/10.1111/ajt.17049.CrossRefPubMedPubMedCentral

27.

Correale M, Mazzeo P, Tricarico L, Croella F, Fortunato M, Magnesa M, et al. Pharmacological anti-remodelling effects of disease-modifying drugs in heart failure with reduced ejection fraction. Clin Drug Investig. 2022;42(7):567–79. https://doi.org/10.1007/s40261-022-01166-2.CrossRefPubMed

28.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038.CrossRefPubMed

Titel: An Overview of the Clinical Implications of Cirrhotic Cardiomyopathy
verfasst von: Sarah Myers
Pakinam Mekki
Manhal Izzy
Publikationsdatum: 08.03.2024
Verlag: Springer US
Erschienen in: Current Hepatology Reports
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00665-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen